HHS Secretary Xavier Becerra (Andrew Harnik/AP Images)
May 31, 2022 12:14 PM EDT
Pharma

Medicare does­n't re­duce its 2022 pre­mi­um hike even as use of Bio­gen's Alzheimer's drug is sharply cur­tailed

Zachary Brennan

Senior Editor

The prospect of the Cen­ters for Medicare & Med­ic­aid Ser­vices (CMS) pay­ing for Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm opened up a mul­ti-bil­lion-dol­lar can of worms …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times